Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.

Intuitive Surgical reported Q1 revenue up 23% YoY to $2.77B and EPS up 18.7% YoY to $2.28, alongside instrument usage rising 16% YoY to 847,000 procedures. While investors panicked about planned 2027 instrument lifetime changes, Goldman argues the force-feedback lifespan extension (6 to 15 uses for 5 of 6 tools) is supply-chain driven with zero impact on revenue per procedure, and expects only ~1% annual decline. Despite a premium valuation (>49x trailing earnings), Goldman raised its price target to $558 after downgrades from several other banks, with July earnings flagged as the key validation point.

Analysis

The market is treating instrument-life extension as a recurring-revenue impairment, but the more important mechanism is customer economics: lower per-case tooling cost can increase procedure throughput and make the platform harder to displace. That matters because the biggest threat to ISRG is not a 1% hit to revenue-per-procedure; it is any slowdown in installed-base conversion or procedure growth. If management can show that cheaper utilization broadens adoption without changing surgeon preference, the bear case on consumables durability weakens materially.

The near-term risk is multiple compression, not a fundamental break. A stock at a premium multiple can absorb only so much uncertainty, so the July print is the key catalyst: any sign that the 2027 change is poorly understood, or that procedure growth slips into the low double digits, will keep de-rating pressure intact. Falsifiers for the bull thesis are straightforward: U.S. revenue-per-procedure down more than ~2-3%, procedure growth decelerating below management’s recent run-rate, or competitive commentary that suggests Hugo/Ottava are gaining share in high-value accounts.

Contrarian view: consensus is probably over-discounting the recurring revenue haircut and underweighting mix offset from higher-end force-feedback tools plus broader adoption from supply relief. The better trade is relative value, not a hero long: if ISRG’s economics hold, MDT and JNJ still need to prove their robotic platforms can convert skepticism into actual placements. Over 6-18 months, this is a durability-and-execution story; over 1-3 months, it is a sentiment and disclosure story.

Key Decisions for Investors

• Start a tactical long ISRG on post-earnings weakness or any additional 5-8% drawdown into July print; thesis only works if procedure growth stays >12% YoY and management quantifies instrument dilution as immaterial.
• Pair trade: long ISRG / short MDT for 1-3 months. If ISRG confirms the pricing/usage change is adoption-accretive, MDT’s robot narrative remains the cleaner relative loser while waiting for a true product-cycle inflection.
• Do not short ISRG outright into earnings; if bearish, express via a short-dated put spread only after July guidance if revenue-per-procedure declines more than 3% or management gives vague 2027 logistics commentary.
• Set an alert on the July call for installed-base growth and instrument/accessory revenue mix. If install growth stays >10% and consumable dilution is <2%, take profits on any bearish positioning.